ArticleRadiology. Imaging cancer2022
Prediction of Histologic Neoadjuvant Chemotherapy Response in Osteosarcoma Using Pretherapeutic MRI Radiomics.
Open access · diamondAbstract read
In one paragraph
Article in Radiology. Imaging cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Radiomics for predicting sensitivity to neoadjuvant chemotherapy in osteosarcoma: current status and advances.Oncology reviews · 2025Pooled it
- Predicting resistance to neoadjuvant chemotherapy in osteosarcoma using machine learning with clinical data and T2-weighted MRI radiomics.European radiology experimental · 2026Article
- Prognostic and Predictive Value of CD163+ Macrophages for Neoadjuvant Chemotherapy in Osteosarcoma.Biomedicines · 2026Article
- Non-invasive MRI biomarkers for assessment of neoadjuvant chemotherapy response in osteosarcoma: Current techniques and clinical perspectives.Journal of bone oncology · 2026Review
- Deep learning for accurate tumour volume measurement and prediction of therapy response in paediatric osteosarcoma.European radiology · 2026Article
- MRI-based intratumoral and peritumoral radiomics predicting neoadjuvant chemotherapy response in osteosarcoma.Frontiers in oncology · 2026Article
- Dynamic immune state transitions and metastatic niche remodelling drive osteosarcoma evolution as a barrier-restricted immune-cold ecosystem.Frontiers in immunology · 2026Review
- Pathology-interpretable radiomic model for predicting clinical outcome in patients with osteosarcoma: a retrospective, multicenter study.BMC medicine · 2025Article
- Article
- Artificial Intelligence in Primary Malignant Bone Tumor Imaging: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- The presence of a fat layer after neoadjuvant chemotherapy as an indicator of prognosis in osteosarcoma.Frontiers in oncology · 2025Article
- Prediction of tumor response to neoadjuvant chemotherapy in high-grade osteosarcoma using clustering-based analysis of magnetic resonance imaging: an exploratory study.La Radiologia medica · 2025Article
- Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024).The archives of bone and joint surgery · 2025Review
- Development of a Secure Web-Based Medical Imaging Analysis Platform: The AWESOMME Project.Journal of imaging informatics in medicine · 2024Article
- Imaging of Osteosarcoma: Presenting Findings, Metastatic Patterns, and Features Related to Prognosis.Journal of clinical medicine · 2024Review
- Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.iScience · 2024Review
- Epstein-Barr virus positive gastric cancer: the pathological basis of CT findings and radiomics models prediction.Abdominal radiology (New York) · 2024Article
- Advancing Pediatric Sarcomas through Radiomics: A Systematic Review and Prospective Assessment Using Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS).Diagnostics (Basel, Switzerland) · 2024Review
- CT and MRI radiomics of bone and soft-tissue sarcomas: an updated systematic review of reproducibility and validation strategies.Insights into imaging · 2024Article
- MRI radiomics captures early treatment response in patient-derived organoid endometrial cancer mouse models.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Amine BouhamamaFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).ORCID 0000-0003-0655-6678
Benjamin LeporqFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).ORCID 0000-0002-3408-4156
Wassef KhaledFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Angéline NemethFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Mehdi BrahmiFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Julie DufauFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Perrine Marec-BérardFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Jean-Luc DrapéFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
François GouinFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Axelle Bertrand-VasseurFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Jean-Yves BlayFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Olivier BeufFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Frank PilleulFrom the Departments of Radiology (A.B., F.P.), Medical Oncology (M.B., J.Y.B.), and Surgery (F.G.), Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, 69008 Lyon, France; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, Lyon, France (A.B., B.L., A.N., O.B., F.P.); Department of Radiology, AP-HP Hôpital Cochin, Paris, France (W.K., J.L.D.); Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France (J.D., P.M.B.); and Department of Radiology, Centre Hospitalier Universitaire de Nantes, Nantes, France (A.B.V.).
Université Claude Bernard Lyon 1 · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histologic response to chemotherapy for osteosarcoma is one of the most important prognostic factors for survival, but assessment occurs after surgery. Although tumor imaging is used for surgical planning and follow-up, it lacks predictive value. Therefore, a radiomics model was developed to predict the response to neoadjuvant chemotherapy based on pretreatment T1-weighted contrast-enhanced MRI. A total of 176 patients (median age, 20 years [range, 5-71 years]; 107 male patients) with osteosarcoma treated with neoadjuvant chemotherapy and surgery between January 2007 and December 2018 in three different centers in France (Centre Léon Bérard in Lyon, Centre Hospitalier Universitaire de Nantes in Nantes, and Hôpital Cochin in Paris) were retrospectively analyzed. Various models were trained from different configurations of the data sets. Two different methods of feature selection were tested with and without ComBat harmonization (ReliefF and
Indexed as
Bone NeoplasmsOsteosarcomaAdultChildHumansMagnetic Resonance ImagingMaleNeoadjuvant TherapyRetrospective StudiesYoung AdultMRIOncologyOsteosarcomaPediatricsRadiomicsSkeletal-Axial
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.